Quality biotechnology news in 2022? BioTech Health X brings you the latest professional biotech news including breaking news on the latest biotechnology research, emerging companies, biotech acquisitions, funding deals and other industry analysis. We focus on covering the latest updates in biotech including clinical research, drug development, drug discovery, clinical trials, FDA decisions and other development information regarding the Life Sciences industry.
Toyobo Co., Ltd. has launched a major U.S. marketing initiative for Nerbridge TM (“the product”, hereafter), a conduit for peripheral nerve regeneration. On January 11, 2022, Toyobo kicked off the sales promotion campaign at a conference jointly held in Carlsbad, California, by three societies – the American Association for Hand Surgery (AAHS), the American Society for Peripheral Nerve (ASPN) and the American Society for Reconstructive Microsurgery (ASRM). The campaign is being conducted in partnership with the exclusive U.S. distributor of Nerbridge TM, Synovis Micro Companies Alliance, Inc. (hereafter Synovis), a subsidiary of Baxter International Inc., a global medtech leader. Toyobo plans to enhance the production capacity of the product by the end of 2025 as well as expanding the scope of its clinical applications. To respond to the increasing demand expected for nerves conduits in the U.S. and elsewhere in the world, Toyobo will strengthen its production and sales capacities, thus becoming the leading company in the nerve conduit business field.
Though clinical trials in the DMD space have progressed, CureDuchenne is aware of the limitations these therapies present. This has driven our global strategy. That’s what FUTURES is going to lay out for the parents and for the families. They’ll see for the first time where we are in gene therapy, the estimate on when these drugs are likely to be approved, and then what’s next. He explained that Adeno-associated virus (AAV) delivery has packing capacity limitations, but Code’s platform does not, which opens the door to formerly impossible investigations. The treatment can be re-dosed, as well. If their technology platform is successful, it has the ability to transform the way we think about delivering much larger gene transcripts and re-dosing.
Biotech Health X delivers the latest research and biotechnology news to help keep you informed on the powerful tools and medicine being developed by scientists, university research programs, new study data and other information linked to humans genes structure and identify the advantage that technology plays in nature and our modern world. From first time breakthrough reports or initial lab studies on mice our team helps to provide coverage and assess the collaboration that exists in the biotechnology field. See more information on https://biotechhealthx.com/.
Global Passive Prosthetics Market – Notable Developments: The technological advancements in recent years have considerably helped the growth of the global passive prosthetics market. Leading companies in the market are launching new products to build better brand value and loyalty. Some of the notable developments in the market are listed below: In September 2019, Steeper Inc. announced that the company has added Lindhe Xtend Connect solution to their lower limb prosthetics product range. The company has teamed up with another promising player in the market Lindhe Xtend. In June 2015, WillowWood Global LLC, a prominent name in the passive prosthetics market announced that the company has teamed up with the OPIE Choice Network. This new agreement allowed WillowWood Global to be the primary line supplier for the network.